We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





New Sensor Uses `Glow-in-the-Dark` Signal to Indicate Presence of Molecules Associated with COVID-19 in Blood

By LabMedica International staff writers
Posted on 29 Jul 2021
A new sensor with bioluminescent proteins indicates the presence of anti-drug antibodies and molecules associated with COVID-19 in the blood.

A research team at Eindhoven University of Technology (Eindhoven, Netherlands) and Utrecht University (Utrecht, the Netherlands) has developed a new type of sensor that combines the sensitivity and accuracy of current laboratory-based measurements with the speed and low-cost of current home tests. More...
The new sensor uses a “glow-in-the-dark” signal to indicate the presence of tiny amounts proteins and anti-drug antibodies, as well as COVID-19 spike proteins and antibodies in blood.

Home test kits to check for COVID-19 spike proteins and anti-COVID-19 antibodies are fast and simple to use but lack the sensitivity and accuracy of laboratory tests. Another issue with these so-called point-of-use home tests is that they are not accurate enough. With all of this in mind, the research team developed a new test approach with the accuracy and sensitivity of current laboratory-based methods and the speed and low-cost of existing point-of-use tests. The key to detecting and indicating the presence of biomarkers or molecules of interest is bioluminescence, the process that organisms such as fireflies use to produce light. The researchers tested the new sensing approach on a variety of biomarkers, including one to detect bacterial and viral infections (C-reactive protein), using 40 patient samples.

The RAPPID testing platform is definitely rapid in nature, and with a suitable sample holder can be used in conjunction with a smartphone, meaning that it has the potential to be used by anyone, anywhere. However, some work still needs to be done before his new testing platform will become available to the wider public.

“Our new sensor is based on bioluminescence, which we have used extensively in our previous research. If a certain protein or antibody is present in the sample, special proteins called luciferase enzymes will emit light,” said Maarten Merkx from the institute for Complex Molecular Systems (ICMS) at TU/e and research lead for the new study. “In other words, we look for a ‘glow-in-the-dark’ response.”

“We envisage that this testing platform could be used for a broad range of applications such as in rapid screening and testing, for therapeutic antibody-drug monitoring associated with conditions like rheumatoid arthritis and inflammatory bowel disease, and for the rapid detection of infectious diseases that could be associated with future epidemics or pandemics,” added Merkx.

Related Links:
Eindhoven University of Technology
Utrecht University



Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Online QC Software
Acusera 24•7
Rapid Sepsis Test
SeptiCyte RAPID
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.